La Jolla Pharmaceutical Company's ability to collect accounts receivable sequentially worsen to 6.4, indicating more challenging environment then in the first quarter 2022, but still, it is a far cry from any concerns. La Jolla Pharmaceutical's Accounts Receivable average collection period in the Jun 30 2022 quarter, has increased to 57 days, from 56 days, in the Mar 31 2022 quarter.

If we take a look into Healthcare sector 280 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. 2214.

What is Receivable Turnover Ratio?
What is La Jolla Pharmaceutical Company Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

LJPC Receivables Turnover Ratio	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter	(Dec 31 2021) IV. Quarter	(Sep 30 2021) III. Quarter	(Jun 30 2021) II. Quarter
Y / Y Receivable Change	-31.05 %	37.95 %	47.58 %	123.8 %	366.41 %
Y / Y Revenue Change	-34.35 %	-69.46 %	11.5 %	46.76 %	176.64 %
Receivable Turnover Ratio (TTM)	6.4	6.56	10.05	10.88	12.48
LJPC's Total Ranking	# 2214	# 2214	# 2214	# 2253	# 2200
Accounts Receivable average collection period days	57	56	36	34	29
Seq. Receivable Change	3.46 %	-33.46 %	-2.08 %	2.29 %	106.98 %
Seq. Revenue Change	1.13 %	-14.62 %	-8.29 %	-17.09 %	-52.96 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 19
Healthcare Sector	# 281
Overall Market	# 2214

Receivable Turnover Ratio Statistics
High	Average	Low
0.82	0.37	0.04
(Sep 30 2021)		(Dec 31 2018)

LJPC Company Profile • Back to LJPC Efficiency Comparisons • Compare LJPC Receivables Turnover Ratio to its Competitors

Financial Statements
La Jolla Pharmaceutical's Accounts Receivable	$ 6 Millions	Visit LJPC's Balance sheet
La Jolla Pharmaceutical's Sales TTM	$ 46 Millions	Visit LJPC's Income Statement
Sources of LJPC's Revenues		Visit LJPC's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
LJPC's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
LJPC's Growth Rates	LJPC's Roa	LJPC's Inventory Turnover Ratio	LJPC's Dividend Comparisons
LJPC's Profitability Ratios	LJPC's Roi	LJPC's Asset Turnover Ratio	LJPC's Dividend Growth
LJPC's Valuation Ratios	LJPC's Roe	LJPC's Financial Strength Ratios	LJPC's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2022, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2022	Receivable at quarter ending Jun 30 2022
Strata Critical Medical Inc	21.44	$ 124.456 Millions	$ 5.805 Millions
Advanced Container Technologies Inc	20.89	$ 4.383 Millions	$ 0.210 Millions
Delcath Systems Inc	20.88	$ 3.806 Millions	$ 0.182 Millions
Vystar Corporation	20.73	$ 15.599 Millions	$ 0.752 Millions
Catalyst Pharmaceuticals Inc	20.43	$ 170.465 Millions	$ 8.346 Millions
Bluebird Bio Inc	20.30	$ 6.089 Millions	$ 0.300 Millions
Valion Bio Inc	20.16	$ 1.517 Millions	$ 0.075 Millions
Intellia Therapeutics Inc	19.76	$ 45.340 Millions	$ 2.294 Millions
Biomerica Inc	19.71	$ 18.871 Millions	$ 0.957 Millions
23andme Holding Co	19.60	$ 277.167 Millions	$ 14.142 Millions
The Oncology Institute Inc	19.44	$ 371.360 Millions	$ 19.101 Millions
Bellicum Pharmaceuticals Inc	18.83	$ 5.541 Millions	$ 0.294 Millions
Vireo Growth Inc.	18.78	$ 63.754 Millions	$ 3.395 Millions
Theralink Technologies Inc	18.74	$ 0.542 Millions	$ 0.029 Millions
Innovage Holding Corp	18.63	$ 698.640 Millions	$ 37.497 Millions
Immunogen inc	18.48	$ 89.442 Millions	$ 4.839 Millions
Vtv Therapeutics Inc	17.94	$ 5.018 Millions	$ 0.280 Millions
Lftd Partners Inc	17.79	$ 56.474 Millions	$ 3.175 Millions
Qhslab Inc	17.17	$ 1.361 Millions	$ 0.079 Millions
Ngm Biopharmaceuticals Inc	17.06	$ 68.775 Millions	$ 4.031 Millions
Chemed Corporation	16.90	$ 2,151.852 Millions	$ 127.321 Millions
Histogen Inc	16.82	$ 4.356 Millions	$ 0.259 Millions
Statera Biopharma Inc fka Cytocom Inc	16.68	$ 3.254 Millions	$ 0.195 Millions
Electrocore Inc	16.48	$ 7.034 Millions	$ 0.427 Millions
Sangamo Therapeutics Inc	16.00	$ 114.158 Millions	$ 7.134 Millions
Finch Therapeutics Group Inc	15.89	$ 12.864 Millions	$ 0.810 Millions
Ethema Health Corporation	15.72	$ 3.917 Millions	$ 0.249 Millions
Neurometrix Inc	15.26	$ 8.325 Millions	$ 0.545 Millions
Travere Therapeutics Inc	14.98	$ 228.120 Millions	$ 15.224 Millions
Nutriband Inc	14.75	$ 1.709 Millions	$ 0.116 Millions

Date modified: 2026-08-29T17:16:58+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.